Connex Platform
Evergreen, network science-based drug discovery platform combining identification of Core transcription factor targets (Core TFs) and design of hyperOligo drug design to treat a broad range of diseases. Initial indications include:
Cancer
Breast and ovarian cancers
Acute myeloid leukemia
Hepatocarcinoma
CNS
Amyotrophic
lateral sclerosis
Fibrosis
Liver fibrosis
Cardio
vascular
Acute and chronic myocardial diseases
hyperOligo DNA drugs
Core Bio algorithcally designs hyperOligos to inhibit multiple Core TFs with a single molecule.
hypeOligos are a class of oligonucleotides with unique drug properties:
- Potent inhibitors of transcription factor activity
- Natural entry into cells and cell nuclei without the need to enhance cellular uptake
- Distribute broadly to tissues including solid tumors
- Well tolerated
- Produce profound and specific therapeutic effects in vivo